13.53

1.96% 0.26

After Hours: 13.52 -0.010 -0.07%

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $13.53, with a volume of 280.77K. It is up +1.96% in the last 24 hours and down -8.08% over the past month. NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Previous Close:

$13.27

Open:

$13.47

24h Volume:

280.77K

Relative Volume:

1.29

Market Cap:

$455.51M

Revenue:

$99.99M

Net Income/Loss:

$-21.47M

P/E Ratio:

-20.51

EPS:

-0.6597

Net Cash Flow:

$-11.34M

1W Performance:

-0.22%

1M Performance:

-8.08%

6M Performance:

+35.16%

1Y Performance:

+11.54%

1-Day Range:

$13.14

$13.73

1-Week Range:

$12.68

$13.74

52-Week Range:

$7.5625

$18.98

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1114)

Industry

Medical Devices (143)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

209

Twitter

Next Earnings Date

2026-03-03

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	13.53	446.76M	99.99M	-21.47M	-11.34M	-0.6597
ABT Abbott Laboratories	104.83	180.82B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	327.65	125.72B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.89	111.16B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	69.78	101.28B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	82.67	47.45B	6.07B	1.06B	1.34B	1.8063

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Initiated	H.C. Wainwright	Buy
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

Mar 25, 2026

NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan

Mar 25, 2026

Aug Selloffs: What makes NeuroPace Inc stock attractive todayMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn

Mar 25, 2026

Mar 24, 2026

Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan

Mar 24, 2026

Director at NeuroPace (NPCE) receives 865-share stock grant - Stock Titan

Mar 24, 2026

Mar 23, 2026

NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan

Mar 23, 2026

NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan

Mar 23, 2026

Mar 21, 2026